Jorge Reis-Filho: A great opportunity to learn more about the exciting work being done at AstraZeneca
Jorge Reis-Filho, Vice President, Cancer Biomarker Development at AstraZeneca, shared a post by
“Looking forward to seeing Diana Merino Vega present how MRD assessment by ctDNA is transforming precision oncology at the National Cancer Institute’s ‘New Frontiers in Liquid Biopsies’ conference next week.
A great opportunity to learn more about the exciting work being done at AstraZeneca to drive precision medicine through innovations in liquid biopsies.”
Quoting
“Quick reminder: David Fabrizio and I will be hosting a lunchtime session next week at the National Cancer Institute (NCI)’s conference on New Frontiers in Liquid Biopsies.
We’ll be discussing how we leverage insights of molecular residual disease (MRD) to propel precision medicine.
The field of liquid biopsy research is evolving rapidly, and I’m looking forward to discussing the potential MRD has in driving innovative solutions in this crucial area of cancer research.
You can find out more here.”
Source: Jorge Reis-Filho/LinkedIn and Diana Merino Vega/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023